Central functional response to the novel peptide cannabinoid, hemopressin

Neuropharmacology

Volumn 71, Issue , 2013, Pages 27-36

  Dodd, Garron T ^a   Worth, Amy A ^a   Hodkinson, Duncan J ^b   Srivastava, Raj K ^c   Lutz, Beat ^c   Williams, Steve R ^b   Luckman, Simon M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Appetite; BOLD fMRI; CB1; Hemopressin; MRI; Nociception; Pharmacological challenge

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; CANNABINOID 1 RECEPTOR AGONIST; HEMOPRESSIN; PROTEIN C FOS; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BOLD SIGNAL; BRAIN MAPPING; BRAIN REGION; CONTROLLED STUDY; DORSAL RAPHE NUCLEUS; DRUG RESPONSE; FEEDING; LIMBIC SYSTEM; MALE; MEDIOBASAL HYPOTHALAMUS; NERVE CELL NETWORK; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEUS ACCUMBENS; ORBITAL CORTEX; PERIAQUEDUCTAL GRAY MATTER; PRIORITY JOURNAL; RAT; REWARD; VENTRAL TEGMENTUM;

ANIMALS; APPETITE DEPRESSANTS; BEHAVIOR, ANIMAL; CANNABINOIDS; HEMOGLOBINS; HYPOTHALAMUS, MIDDLE; INJECTIONS, INTRAPERITONEAL; MALE; MICE; MICE, KNOCKOUT; NERVE TISSUE PROTEINS; NEURONS; PEPTIDE FRAGMENTS; PERIAQUEDUCTAL GRAY; PIPERIDINES; PYRAZOLES; RANDOM ALLOCATION; RAPHE NUCLEI; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; SATIETY RESPONSE;

EID: 84878132837     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2013.03.007     Document Type: Article

References (69)

1. K.V. Allen, I.S. McGregor, G.E. Hunt, M.E. Singh, and P.E. Mallet Regional differences in naloxone modulation of Delta(9)-THC induced Fos expression in rat brain Neuropharmacology 44 2003 264 274
2. B.D. Bennett, and J.P. Bolam Synaptic input and output of parvalbumin-immunoreactive neurons in the neostriatum of the rat Neuroscience 62 1994 707 719
3. T. Bisogno Endogenous cannabinoids: structure and metabolism J. Neuroendocrinol. 20 Suppl. 1 2008 1 9
4. C.S. Breivogel, L.J. Sim, and S.R. Childers Regional differences in cannabinoid receptor/G-protein coupling in rat brain J. Pharmacol. Exp. Ther. 282 1997 1632 1642
5. F.Y. Che, X. Zhang, I. Berezniuk, M. Callaway, J. Lim, and L.D. Fricker Optimization of neuropeptide extraction from the mouse hypothalamus J. Proteome Res. 6 2007 4667 4676
6. R. Christensen, P.K. Kristensen, E.M. Bartels, H. Bliddal, and A. Astrup Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials Lancet 370 2007 1706 1713
7. J.F. Deakin, J. Lees, S. McKie, J.E. Hallak, S.R. Williams, and S.M. Dursun Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study Arch. Gen. Psychiatry 65 2008 154 164
8. V. Di Marzo The endocannabinoid system in obesity and type 2 diabetes Diabetologia 51 2008 1356 1367
9. V. Di Marzo Endocannabinoids: an appetite for fat Proc. Natl. Acad. Sci. U. S. A. 108 2011 12567 12568
10. V. Di Marzo, M. Bifulco, and L. De Petrocellis The endocannabinoid system and its therapeutic exploitation Nat. Rev. Drug Discov. 3 2004 771 784
11. V. Di Marzo, F. Piscitelli, and R. Mechoulam Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes Handb. Exp. Pharmacol. 2011 75 104
12. G.T. Dodd, G. Mancini, B. Lutz, and S.M. Luckman The peptide hemopressin acts through CB1 cannabinoid receptors to reduce food intake in rats and mice J. Neurosci. 30 2010 7369 7376
13. G.T. Dodd, J.A. Stark, S. McKie, S.R. Williams, and S.M. Luckman Central cannabinoid signaling mediating food intake: a pharmacological-challenge magnetic resonance imaging and functional histology study in rat Neuroscience 163 2009 1192 1200
14. G.T. Dodd, S.R. Williams, and S.M. Luckman Functional magnetic resonance imaging and c-Fos mapping in rats following a glucoprivic dose of 2-deoxy-D-glucose J. Neurochem. 113 2010 1123 1132
15. A. Dogrul, M. Seyrek, B. Yalcin, and A. Ulugol Involvement of descending serotonergic and noradrenergic pathways in CB(1) receptor-mediated antinociception Prog. Neuropsychopharmacol. Biol. Psychiatry 2012
16. S.J. Gatley, R. Lan, B. Pyatt, A.N. Gifford, N.D. Volkow, and A. Makriyannis Binding of the non-classical cannabinoid CP 55,940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors Life Sci. 61 1997 191 197
17. I. Gomes, J.S. Grushko, U. Golebiewska, S. Hoogendoorn, A. Gupta, A.S. Heimann, E.S. Ferro, S. Scarlata, L.D. Fricker, and L.A. Devi Novel endogenous peptide agonists of cannabinoid receptors FASEB J. 23 2009 3020 3029
18. R. Gomez, M. Navarro, B. Ferrer, J.M. Trigo, A. Bilbao, I. Del Arco, A. Cippitelli, F. Nava, D. Piomelli, and F. Rodriguez de Fonseca A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding J. Neurosci. 22 2002 9612 9617
19. A. Gozzi, V. Colavito, P.F. Seke Etet, D. Montanari, S. Fiorini, S. Tambalo, A. Bifone, G.G. Zucconi, and M. Bentivoglio Modulation of fronto-cortical activity by modafinil: a functional imaging and fos study in the rat Neuropsychopharmacology 37 2012 822 837
20. G. Griebel, J. Stemmelin, and B. Scatton Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents Biol. Psychiatry 57 2005 261 267
21. L. Guasti, D. Richardson, M. Jhaveri, K. Eldeeb, D. Barrett, M.R. Elphick, S.P. Alexander, D. Kendall, G.J. Michael, and V. Chapman Minocycline treatment inhibits microglial activation and alters spinal levels of endocannabinoids in a rat model of neuropathic pain Mol. Pain 5 2009 35
22. S.L. Haberny, Y. Berman, E. Meller, and K.D. Carr Chronic food restriction increases D-1 dopamine receptor agonist-induced phosphorylation of extracellular signal-regulated kinase 1/2 and cyclic AMP response element-binding protein in caudate-putamen and nucleus accumbens Neuroscience 125 2004 289 298
23. A. Hama, and J. Sagen Activation of spinal and supraspinal cannabinoid-1 receptors leads to antinociception in a rat model of neuropathic spinal cord injury pain Brain Res. 1412 2011 44 54
24. A. Hama, and J. Sagen Centrally mediated antinociceptive effects of cannabinoid receptor ligands in rat models of nociception Pharmacol. Biochem. Behav. 100 2011 340 346
25. Z. Hawke, T.R. Ivanov, D.A. Bechtold, H. Dhillon, B.B. Lowell, and S.M. Luckman PACAP neurons in the hypothalamic ventromedial nucleus are targets of central leptin signaling J. Neurosci. 29 2009 14828 14835
26. D.J. Heeger, A.C. Huk, W.S. Geisler, and D.G. Albrecht Spikes versus BOLD: what does neuroimaging tell us about neuronal activity? Nat. Neurosci. 3 2000 631 633
27. A.S. Heimann, I. Gomes, C.S. Dale, R.L. Pagano, A. Gupta, L.L. de Souza, A.D. Luchessi, L.M. Castro, R. Giorgi, V. Rioli, E.S. Ferro, and L.A. Devi Hemopressin is an inverse agonist of CB1 cannabinoid receptors Proc. Natl. Acad. Sci. U. S. A. 104 2007 20588 20593
28. M. Herkenham, A.B. Lynn, M.R. Johnson, L.S. Melvin, B.R. de Costa, and K.C. Rice Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study J. Neurosci. 11 1991 563 583
29. H. Hermann, G. Marsicano, and B. Lutz Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain Neuroscience 109 2002 451 460
30. A.G. Hohmann, and R.L. Suplita 2nd Endocannabinoid mechanisms of pain modulation AAPS J. 8 2006 E693 E708
31. M. Kano, T. Ohno-Shosaku, Y. Hashimotodani, M. Uchigashima, and M. Watanabe Endocannabinoid-mediated control of synaptic transmission Physiol. Rev. 89 2009 309 380
32. A.E. Kelley, B.A. Baldo, W.E. Pratt, and M.J. Will Corticostriatal- hypothalamic circuitry and food motivation: integration of energy, action and reward Physiol. Behav. 86 2005 773 795
33. A.E. Kelley, and C.J. Swanson Feeding induced by blockade of AMPA and kainate receptors within the ventral striatum: a microinfusion mapping study Behav. Brain Res. 89 1997 107 113
34. T.C. Kirkham Cannabinoids and appetite: food craving and food pleasure Int. Rev. Psychiatry 21 2009 163 171
35. T.C. Kirkham, C.M. Williams, F. Fezza, and V. Di Marzo Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol Br. J. Pharmacol. 136 2002 550 557
36. K.J. Kovacs Measurement of immediate-early gene activation - c-fos and beyond J. Neuroendocrinol. 20 2008 665 672
37. G. Kunos, D. Osei-Hyiaman, S. Batkai, K.A. Sharkey, and A. Makriyannis Should peripheral CB(1) cannabinoid receptors be selectively targeted for therapeutic gain? Trends Pharmacol. Sci. 30 2009 1 7
38. F. Luo, G. Wu, Z. Li, and S.J. Li Characterization of effects of mean arterial blood pressure induced by cocaine and cocaine methiodide on BOLD signals in rat brain Magn. Reson. Med. 49 2003 264 270
39. F. Maekawa, K. Fujiwara, S. Tsukahara, and T. Yada Pituitary adenylate cyclase-activating polypeptide neurons of the ventromedial hypothalamus project to the midbrain central gray Neuroreport 17 2006 221 224
40. G. Marsicano, C.T. Wotjak, S.C. Azad, T. Bisogno, G. Rammes, M.G. Cascio, H. Hermann, J. Tang, C. Hofmann, W. Zieglgansberger, V. Di Marzo, and B. Lutz The endogenous cannabinoid system controls extinction of aversive memories Nature 418 2002 530 534
41. W.J. Martin, P.O. Coffin, E. Attias, M. Balinsky, K. Tsou, and J.M. Walker Anatomical basis for cannabinoid-induced antinociception as revealed by intracerebral microinjections Brain Res. 822 1999 237 242
42. W.J. Martin, S.L. Patrick, P.O. Coffin, K. Tsou, and J.M. Walker An examination of the central sites of action of cannabinoid-induced antinociception in the rat Life Sci. 56 1995 2103 2109
43. S. McKie, P. Richardson, R. Elliott, B.A. Vollm, M.C. Dolan, S.R. Williams, I.M. Anderson, and J.F. Deakin Mirtazapine antagonises the subjective, hormonal and neuronal effects of m-chlorophenylpiperazine (mCPP) infusion: a pharmacological-challenge fMRI (phMRI) study Neuroimage 58 2011 497 507
44. R. Monhemius, J. Azami, D.L. Green, and M.H. Roberts CB1 receptor mediated analgesia from the Nucleus Reticularis Gigantocellularis pars alpha is activated in an animal model of neuropathic pain Brain Res. 908 2001 67 74
45. D.G. Nair About being BOLD Brain Res. Rev. 50 2005 229 243
46. E. Nakazato, A. Kato, and S. Watanabe Brain but not spinal NR2B receptor is responsible for the anti-allodynic effect of an NR2B subunit-selective antagonist CP-101,606 in a rat chronic constriction injury model Pharmacology 73 2005 8 14
47. R. Nogueiras, C. Veyrat-Durebex, P.M. Suchanek, M. Klein, J. Tschop, C. Caldwell, S.C. Woods, G. Wittmann, M. Watanabe, Z. Liposits, C. Fekete, O. Reizes, F. Rohner-Jeanrenaud, and M.H. Tschop Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats Diabetes 57 2008 2977 2991
48. W. Olango, M. Roche, G. Ford, B. Harhen, and D. Finn The endocannabinoid system in the rat dorsolateral periaqueductal grey mediates fear-conditioned analgesia and controls fear expression in the presence of nociceptive tone Br. J. Pharmacol. 165 2011 2549 2560
49. G. Paxinos, and C. Watson The Rat Brain in Stereotaxic Coordinates 1998 San Diego Academic Press
50. R.G. Pertwee Pharmacological actions of cannabinoids Handb. Exp. Pharmacol. 2005 1 51
51. S. Petrosino, and V. Di Marzo FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels Curr. Opin. Investig. Drugs 11 2010 51 62
52. S. Petrosino, E. Palazzo, V. de Novellis, T. Bisogno, F. Rossi, S. Maione, and V. Di Marzo Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats Neuropharmacology 52 2007 415 422
53. E.J. Rahn, and A.G. Hohmann Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside Neurotherapeutics 6 2009 713 737
54. P. Ramos-Cabrer, R. Weber, D. Wiedermann, and M. Hoehn Continuous noninvasive monitoring of transcutaneous blood gases for a stable and persistent BOLD contrast in fMRI studies in the rat NMR Biomed. 18 2005 440 446
55. V. Rioli, F.C. Gozzo, A.S. Heimann, A. Linardi, J.E. Krieger, C.S. Shida, P.C. Almeida, S. Hyslop, M.N. Eberlin, and E.S. Ferro Novel natural peptide substrates for endopeptidase 24.15, neurolysin, and angiotensin-converting enzyme J. Biol. Chem. 278 2003 8547 8555
56. A.J. Schwarz, A. Danckaert, T. Reese, A. Gozzi, G. Paxinos, C. Watson, E.V. Merlo-Pich, and A. Bifone A stereotaxic MRI template set for the rat brain with tissue class distribution maps and co-registered anatomical atlas: application to pharmacological MRI Neuroimage 32 2006 538 550
57. V. Scott, N. Kimura, J.A. Stark, and S.M. Luckman Intravenous peptide YY3-36 and Y2 receptor antagonism in the rat: effects on feeding behaviour J. Neuroendocrinol. 17 2005 452 457
58. M.E. Singh, A.N. Verty, I. Price, I.S. McGregor, and P.E. Mallet Modulation of morphine-induced Fos-immunoreactivity by the cannabinoid receptor antagonist SR 141716 Neuropharmacology 47 2004 1157 1169
59. P. Sinnayah, E.E. Jobst, J.A. Rathner, A.D. Caldera-Siu, L. Tonelli-Lemos, A.J. Eusterbrock, P.J. Enriori, E.N. Pothos, K.L. Grove, and M.A. Cowley Feeding induced by cannabinoids is mediated independently of the melanocortin system PLoS ONE 3 2008 e2202
60. J.A. Stark, K.E. Davies, S.R. Williams, and S.M. Luckman Functional magnetic resonance imaging and c-Fos mapping in rats following an anorectic dose of m-chlorophenylpiperazine Neuroimage 31 2006 1228 1237
61. B.E. Sumner, L.A. Cruise, D.A. Slattery, D.R. Hill, M. Shahid, and B. Henry Testing the validity of c-fos expression profiling to aid the therapeutic classification of psychoactive drugs Psychopharmacology (Berl.) 171 2004 306 321
62. Z.D. Thornton-Jones, G.A. Kennett, S.P. Vickers, and P.G. Clifton A comparison of the effects of the CB(1) receptor antagonist SR141716A, pre-feeding and changed palatability on the microstructure of ingestive behaviour Psychopharmacology (Berl.) 193 2007 1 9
63. Z.D. Thornton-Jones, S.P. Vickers, and P.G. Clifton The cannabinoid CB1 receptor antagonist SR141716A reduces appetitive and consummatory responses for food Psychopharmacology (Berl.) 179 2005 452 460
64. O. Valverde, M. Karsak, and A. Zimmer Analysis of the endocannabinoid system by using CB1 cannabinoid receptor knockout mice Handb. Exp. Pharmacol. 2005 117 145
65. L.F. Van Gaal, A.M. Rissanen, A.J. Scheen, O. Ziegler, and S. Rossner Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study Lancet 365 2005 1389 1397
66. C.W. Vaughan, M. Connor, E.E. Bagley, and M.J. Christie Actions of cannabinoids on membrane properties and synaptic transmission in rat periaqueductal gray neurons in vitro Mol. Pharmacol. 57 2000 288 295
67. J.M. Walker, and A.G. Hohmann Cannabinoid mechanisms of pain suppression Handb. Exp. Pharmacol. 2005 509 554
68. R.I. Wilson, and R.A. Nicoll Endocannabinoid signaling in the brain Science 296 2002 678 682
69. C.Z. Zhu, J.P. Mikusa, Y. Fan, P.R. Hollingsworth, M. Pai, P. Chandran, A.V. Daza, B.B. Yao, M.J. Dart, M.D. Meyer, M.W. Decker, G.C. Hsieh, and P. Honore Peripheral and central sites of action for the non-selective cannabinoid agonist WIN 55,212-2 in a rat model of post-operative pain Br. J. Pharmacol. 157 2009 645 655